Disease Landscape and Forecast Insights

Cancer treatment is rapidly evolving and demand for more than modest incremental efficacy gains in highly competitive markets is growing. Given the complexity of the multiple pathways and aberrant…

The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…

How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…

Biologics prescribed by rheumatologists and gastroenterologists are among the most commercially successful biopharmaceutical products in the world. These biologics are a prime target for biosimilar…

For the estimated 700,000 people in the United States who suffer from Crohn’s disease (CD), there are multiple prescription therapies that are available for treating the associated symptoms. The…

Last Updated 28 September 2015 The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The…

Dyslipidemia is a risk factor for the development of cardiovascular disease and one of the most prevalent diseases in the United States. The efficacy of statins has led to their dominance in the…

Medical device companies developing products for drug-treated populations must understand the clinical, health economic, and marketing challenges that manifest from this convergence, or risk their…

How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm? Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to…

Increasing formulary competition and decreasing product differentiation have led to an aggressive pricing war in the U.S. asthma and chronic obstructive pulmonary disorder (COPD) markets. As…

Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…

Gram-negative pathogens (GNPs) are clinically important pathogens in both the hospital and outpatient settings. GNPs are often acquired in healthcare facilities, and therefore have a high incidence…